Selection Criteria to Protect the Blood Donor in North America and Europe: Past (Dogma), Present (Evidence), and Future (Hemovigilance)

Transfusion Medicine Reviews

Volumn 23, Issue 3, 2009, Pages 205-220

  Eder, Anne ^a,b,c,d,e   Goldman, Mindy ^a,b,c,d,e   Rossmann, Susan ^a,b,c,d,e   Waxman, Dan ^a,b,c,d,e   Bianco, Celso ^a,b,c,d,e  

^a AMERICAN RED CROSS   (United States)

^b Canadian Forest Service   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d Central Indiana Regional Blood Center   (United States)

^e America's Blood Centers   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; HEMOGLOBIN; INFLIXIMAB; METHOTREXATE; PREDNISONE;

AGE; ANAMNESIS; ARTICLE; AUTOIMMUNE DISEASE; BLOOD ANALYSIS; BLOOD COMPONENT; BLOOD DONOR; BLOOD PRESSURE MEASUREMENT; BLOOD TRANSFUSION; BLOOD VOLUME; BODY WEIGHT; CLINICAL PRACTICE; DONOR SELECTION; DRUG USE; EUROPE; EUROPEAN UNION; EVIDENCE BASED PRACTICE; HEALTH STATUS; HEART DISEASE; HEMATOCRIT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; INFORMED CONSENT; MALIGNANT NEOPLASTIC DISEASE; NORTH AMERICA; PATIENT SAFETY; PULSE RATE; QUALITY CONTROL; QUESTIONNAIRE; RACE DIFFERENCE; RECIPIENT; REFERENCE VALUE; RISK REDUCTION;

BLOOD BANKS; BLOOD DONORS; EUROPE; EVIDENCE-BASED PRACTICE; HUMANS; NORTH AMERICA; PATIENT SELECTION; QUESTIONNAIRES; SAFETY MANAGEMENT;

EID: 67249138001     PISSN: 08877963     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tmrv.2009.03.003     Document Type: Article

References (78)

1. Boulton F. Evidence-based criteria for the care and selection of blood donors, with some comments on the relationship to blood supply, and emphasis on the management of donation-induced iron depletion. Transf Med 18 (2008) 13-27
2. Strauss R.G. Rationale for medical director acceptance or rejection of allogeneic plateletpheresis donors with underlying medical disorders. J Clin Apheresis 17 (2002) 111-117
3. Tomasulo P.A., Anderson A.J., Paluso M.B., et al. A study of criteria for blood donor deferral. Transfusion 20 (1980) 511-518
4. Eder A.F., Bianco C., Rossmann S., et al. International disparities in whole blood donor deferral criteria intended to protect donors. Transfusion 48 (2008) 302A
5. Newman B.H. Blood donor complications after whole-blood donation. Current Opin Hematol 11 (2004) 321-322
6. Wiltbank T.B., and Giordano G.F. The safety profile of automated collections: An analysis of more than 1 million collections. Transfusion 47 (2007) 1002-1005
7. Eder A.F., Dy B.A., Kennedy J.M., et al. The American Red Cross donor hemovigilance program: Complications of blood donation reported in 2006. Transfusion 48 (2008) 1809-1819
8. Bianco C., Brittenham G., Gilcher R.O., et al. Maintaining iron balance in women blood donors of childbearing age: Summary of a workshop. Transfusion 42 (2002) 798-805
9. Custer B., Chinn A., Hirschler N.V., et al. The consequences of temporary deferral on future of whole blood donation. Transfusion 47 (2007) 1514-1523
10. Halperin D., Baetens J., and Newman B. The effect of short-term, temporary deferral on future blood donation. Transfusion 38 (1998) 181-183
11. Zou S., Musavi F., Notari E.P., et al. Donor deferral and resulting donor loss at the American Red Cross Blood Services, 2001 through 2006. Transfusion 48 (2008) 2531-2539
12. France C.R., France J.L., Roussos M., et al. Mild reactions to blood donation predict a decreased likelihood of donor return. Transfus Apher Sci 30 (2004) 17-22
13. Fridey J.L., Townsend M.J., Kessler D.A., et al. A question of clarity: Redesigning the American Association of Blood Banks blood Donor History Questionnaire-A chronology and model for donor screening. Transfus Med Rev 21 (2007) 181-204
14. Busch M.P., Young M.J., Samson S.M., et al. Risk of human immunodeficiency virus transmission by blood transfusions prior to the implementation of HIV antibody screening in the San Francisco Bay Area. Transfusion 31 (1991) 4-11
15. FDA Draft Guidance. Acceptable full-length Donor History Questionnaire and accompanying materials for use in screening human donors of blood and blood components. Available at:. http://www.fda.gov/cber/gdlns/donorhistques.htm
16. AABB. Donor History Questionnaire. Available at:. http://www.aabb.org/Content/Donate_Blood/Donor_History_Questionnaires/AA BB_Blood_Donor_History_Questionnaire
17. Department of Health and Human Services, and Food and Drug Administration. Requirements for Human Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use; Proposed Rule Federal Register: November 8, 2007 (Volume 72, Number 216) 21 CFR Parts 606, 610, et al. Available at:. http://www.fda.gov/cber/rules/reqbldtrans.htm
18. Federal Docket Management System. Public Comment on Docket Number 2006N-0221, 8 November 2007: Requirements for Human Blood and Blood Components Intended for Further Manufacturing Use, Proposed Rule. Available at:. http://www.regulations.gov/search/search_results.jsp?css=0&&Ntk= All&Ntx=mode+matchall&Ne=2+8+11+8053+8054+8098+8074+8066+8084+80 55&N=0&Ntt=2006N-0221&sid=11E8C2529BD9
19. O'Brien S.F., Ram S.S., Vamvakas E.C., et al. The Canadian Blood Donor Health Assessment Questionnaire: Lessons from history, application of cognitive science principles, and recommendations for change. Transfus Med Rev 21 (2007) 205-222
20. Seitz R., Heiden M., Nübling C.M., et al. The harmonization of the regulation of blood products: A European perspective. Vox Sang 94 (2008) 267-276
21. Council of Europe. Guide to the Preparation, Use and Quality Assurance of Blood Components. 14th ed (2008), Council of Europe Publishing, Strasbourg. 978-92-871-5667-9
22. The Commission of European Communities. Directive 2002/98/EC of the European Parliament and of the Council of 27 January 2003 Setting standards of quality and safety for the collection, testing, processing, storage and distribution of human blood and blood components and amending Directive 2001/83/EC. Official Journal of the European Journal. Available at:. http://eurlex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2003:033:0030: 0040:EN:PDF
23. The Commission of European Communities: Commission Directive 2004/33/EC of 22 March 2004 implementing Directive 2002/98/EC of the European Parliament and of the Council as regards certain technical requirements for blood and blood components. Official Journal of the European Union. Available at:. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2004:091:0025 :0039:EN:PDF
24. Follea G.F. Donor selection criteria throughout Europe. Vox Sang 89 (2005) 113-209
25. Chiavetta J.A., Deeks S., Goldman M., et al. Proceedings of a consensus conference: blood-borne HIV and hepatitis-Optimizing the donor selection process. Transfus Med Rev 17 (2003) 1-30
26. Poles F.C., and Boycott M. Syncope in blood donors. Lancet 240 (1942) 531-535
27. Trouern-Trend J.J., Cable R.G., Badon S.J., et al. A case-controlled multicenter study of vasovagal reactions in blood donors: Influence of sex, age, donation status, weight, blood pressure, and pulse. Transfusion 39 (1999) 316-320
28. Newman B.H., Satz S.L., Janowicz N.M., et al. Donor reactions in high-school donors: The effects of sex, weight, and collection volume. Transfusion 46 (2006) 284-288
29. Eder A.F., Hillyer C.D., Dy B.A., et al. Adverse reactions to allogeneic whole blood donation by 16- and 17-year-olds. JAMA 299 (2008) 2279-2286
30. Wiltbank T.B., Giordano G.F., Kamel H., et al. Faint and prefaint reactions in whole-blood donors: An analysis of predonation measurement and their predictive value. Transfusion 48 (2008) 1799-1808
31. Rios J.A., Fang J.Y., Spencer B., et al. Relationship between body mass index and other factors in blood donors having vasovagal reactions. Transfusion 48 (2008) 30A [Suppl]
32. Price T.H. Requirements for allogeneic qualification. Standards for Blood Banks and Transfusion Services. 25th ed (2006), AABB Press, Bethesda (Md)
33. Eder A., Kamel H., France C., et al. Recommendations to minimize the risk of reactions and injuries among adolescent blood donors. AABB Bulletin 08-04, (Appendix1). Available at:. http://www.aabb.org/Content/Members_Area/Association_Bulletins/ab08-04.h tm
34. France C.R., and Menitove J.E. Mitigating adverse reactions in young donors. Transfusion 48 (2008) 1774-1776
35. Goldman M., Fournier E., Cameron-Choi K., et al. Effect of changing the age criteria for blood donors. Vox Sang 92 (2007) 368-372
36. Shehata N., Kusano R., Hannach, et al. Reaction rates in allogeneic donors. Transfusion Med 4 (2004) 327-333
37. Ali A.M., Goldsmith C.H., McAvoy A.T., et al. A prospective study evaluating the lowering of hemoglobin standards for blood donors. Transfusion 29 (1989) 268-272
38. Pi D.W., Krikler S.H., Sparling T.G., et al. Reappraisal of optimal hemoglobin standards for female blood donors in Canada. Transfusion 34 (1994) 7-10
39. Beutler E., and Waalen J. The definition of anemia: What is the lower limit of normal of the blood hemoglobin concentration?. Blood 107 (2006) 1747-1750
40. Fulwood F., Johnson C.I., Bryner J.D., et al. Hematological and nutritional biochemistry reference data for persons 6 months-74 years of age; United States, 1976-1980. Vital and health statistics, Series 11, No 232. CHHS Publication number (PYS) 83-1682 (1982), Public Health Service, National Center for Heath Statistics, Government Printing Office, Washington (DC)
41. Sempos C.T., Looker A.C., Gillum R.F., et al. Body iron stores and the risk of coronary heart disease. N Engl J Med 330 (1994) 1119-1124
42. Meyers D.G., Jensen K.C., and Menitove J.E. A historical cohort study of the effect of lowering body iron through blood donation on incident cardiac events. Transfusion 42 (2002) 1135-1139
43. Ascherio A., Rimm E.B., Giovannucci E., et al. Blood donations and risk of coronary heart disease in men. Circulation 103 (2001) 52-57
44. Murray-Kolb L.E., and Beard J.L. Iron treatment normalizes cognitive functioning in young women. Am J Clin Nutr 85 (2007) 778-787
45. Page E.A., Harrison J.F., Jaldow E.J., et al. Impairment of short-term memory associated with low iron stores in a volunteer multidose plateletpheresis donor. Transfus Med 18 (2008) 312-314
46. Farrugia A. Iron and blood donation-An under recognized safety issue. Dev Biol 127 (2007) 137-146
47. Simon T.L., Garry P.J., and Hooper E.M. Iron stores in blood donors. J Am Med Assoc 245 (1981) 2038-2043
48. Pickering T.G., Hall J.E., Appel L.J., et al. Recommendation for blood pressure measurement in humans and experimental animals. Circulation 111 (2005) 697-716
49. Chobanian A.V., Bakris G.L., Black H.R., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 289 (2003) 2560-2571
50. Tierney W.M., Brunt M., Kesterson J., et al. Quantifying risk of adverse clinical events with one set of vital signs among primary care patients with hypertension. Ann Fam Med 2 (2004) 209-217
51. Newman B., Siegried B., Haley N.R., et al. Quantitative study of contributing factors to vasovagal donor reaction rates in eight blood centers. (abstract). Transfusion 48 (2008) 58A [Suppl 2]
52. AHA Statistical Update. Heart disease and stroke statistics 2007 update. Circulation 115 (2007) e69-e171
53. Agency for Healthcare Research and Quality, Medical Expenditure Panel Survey. Available at:. http://www.meps.ahrq.gov
54. Strupp A. Blood donors with cardiovascular disease. In: Eder A., and Bianco C. (Eds). Screening Blood Donors: Science Reason and the Donor History Questionnaire (2007), AABB Press, Bethesda (Md) 31-55
55. Thomas M.J.G., Gillon J., and Desmond M.J. Preoperative autologous blood donation. Transfusion 36 (1996) 633-639
56. Hillyer C.D., Hart K.K., Lackey III D.A., et al. Comparable safety of blood collection in "high-risk" autologous donors versus non-high-risk autologous and directed donors in a hospital setting. Am J Clin Pathol 102 (1994) 275-277
57. Aubuchon J.P., and Popovsky M.A. The safety of preoperative autologous blood donation in the nonhospital setting. Transfusion 31 (1991) 513-517
58. Domen R., Hnat H., and Panasiuk M. Autologous blood donation by patients with cardiovascular disease. Vox Sang 63 (1992) 137
59. McCarthy L.J., Danielson C., Pugh M., et al. Should cardiac disease prevent autologous blood donation?. Transfus Sci 18 (1997) 81-83
60. Pisciotto P., Sataro P., and Blumberg N. Incidence of adverse reactions in blood donors taking antihypertensive medications. Transfusion 22 (1982) 530-531
61. Eder A. Blood donors with a history of cancer. In: Eder A., and Bianco C. (Eds). Screening Blood Donors: Science Reason and the Donor History Questionnaire (2007), AABB Press, Bethesda (Md) 77-92
62. US. Food and Drug Administration, Center for Biologics Evaluation and Research, Blood Donor Suitability Workshop, December 9, 1999. Available at:. http://www.fda.gov/cber/minutes/donsuit120999.htm
63. Edgren G., Hjalgrim H., Reilly M., et al. Risk of cancer after blood transfusion from donors with subclinical cancer: A retrospective cohort study. Lancet 369 (2007) 1724-1730
64. Purdy E., Jensen K., Perry E., et al. Success of reinstating donors previously deferred five years for history of cancer. Transfusion 45 (2005) 174A
65. Fernandez-Campa G., Bernardo M., Chiin T., et al. The evaluation of blood donor deferral causes. Vox Sang 93 (2007) 63
66. Melanson S.E.F., Stowell C.P., Flood J.G., et al. Does blood donor history accurately reflect the use of prescription medications? A comparison of donor history and serum toxicologic analysis. Transfusion 46 (2006) 1402-1407
67. Gu Q., Paulose-Ram R., Dillon C., et al. Antihypertensive medication use among US adults with hypertension. Circulation 113 (2006) 213-221
68. Lavoie P., Charest L., Germain M., et al. Severe reactions among autologous donors. Transfusion 39 (1999) 30S
69. Land K.J. Medications and Vaccines. In: Eder A., and Bianco C. (Eds). Screening Blood Donors: Science, Reason and the Donor History Questionnaire (2007), AABB Press, Bethesda (Md) 93-120
70. Helmick C.G., Felson D.T., Lawrence R.C., et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 58 (2008) 15-25
71. National Institutes of Diabetes and Digestive and Kidney Diseases, NIH, National Diabetes Statistics, 2007, National Diabetes Information Clearinghouse. http://diabetes.niddk.nih.gov/dm/pubs/statistics/ Accessed February 8, 2009
72. Lampeter E.F., McCann S.R., and Kolb H. Transfer of diabetes type 1 by bone-marrow transplantation. Lancet 351 (1998) 568-569
73. Lee T.H., Paglieroni T., Ohto H., et al. Survival of donor leukocyte subpopulations in immunocompetent transfusion recipients: Frequent long-term microchimerism in severe trauma patients. Blood 93 (1999) 3127-3139
74. Artlett C.M. Microchimerism in health and disease. Curr Mol Med 2 (2002) 525-535
75. International Forum. Haemovigilance. Vox Sang 90 (2006) 207-241
76. Jorgenson J., and and the Working Group on Complications of Blood Donation. Standard for surveillance of complications related to blood donation. 2008. International Society of Blood Transfusion, Working Party on Haemovigilance, European Haemovigilance Network. http://www.isbt-web.org/members_only/files/society/StandardSurveillanceD OCO.pdf Accessed, February 7, 2009
77. Caffrey EA: Adverse events in whole blood donors. Blood matters: Quarterly information for hospitals served by the National Blood Service (newsletter). 2006;19:3-4 http://hospital.blood.co.uk/library/blood_matters/index.asp Accessed February 7, 2009
78. Haemovigilance Working Group. TROLL-the haemovigilance annual report on blood transfusion and donation in Norway (2004). http://www.hemovigilans.no/docs/haemovigilance-english2004%20060901.doc Accessed February 7, 2009